{
    "id": "correct_subsidiary_00046_3",
    "rank": 21,
    "data": {
        "url": "https://www.yumpu.com/en/document/view/408081/gsk-form-20f-2007",
        "read_more_link": "",
        "language": "en",
        "title": "GSK Form 20F 2007",
        "top_image": "https://www.yumpu.com/en/image/facebook/408081.jpg",
        "meta_img": "https://www.yumpu.com/en/image/facebook/408081.jpg",
        "images": [
            "https://assets.yumpu.com/release/Gb2iuBFx8UHm6GO/v5/img/logo/Yumpu_Logo_RGB.png",
            "https://assets.yumpu.com/release/Gb2iuBFx8UHm6GO/v5/img/account/document_privacy_modal/step1.png",
            "https://assets.yumpu.com/release/Gb2iuBFx8UHm6GO/v5/img/account/document_privacy_modal/step2.png",
            "https://img.yumpu.com/408081/1/500x640/gsk-form-20f-2007.jpg",
            "https://assets.yumpu.com/v4/img/avatar/female-200x200.jpg",
            "https://img.yumpu.com/444628/1/190x143/gsk-vaccines-in-2011.jpg?quality=85",
            "https://img.yumpu.com/409221/1/190x245/gsk-seroxat-article-31-question-7-2004.jpg?quality=85",
            "https://img.yumpu.com/408120/1/190x245/gsk-letter-to-hcps-re-paxil-dec-2005.jpg?quality=85",
            "https://img.yumpu.com/408105/1/190x135/climate-change-and-health-framing-the-issue.jpg?quality=85",
            "https://img.yumpu.com/408072/1/190x245/gsk-329-continuation-study-paroxetine.jpg?quality=85",
            "https://img.yumpu.com/408061/1/184x260/glaxosmithkline-sustainability-in-environment-health-and-safety-.jpg?quality=85",
            "https://img.yumpu.com/408030/1/190x245/gsk-seroxat-article-31-question-5.jpg?quality=85",
            "https://img.yumpu.com/408004/1/184x260/form-20-f-glaxosmithkline-plc.jpg?quality=85",
            "https://img.yumpu.com/407974/1/190x245/gsk-contract-manufacturing-steriles.jpg?quality=85",
            "https://img.yumpu.com/407965/1/184x260/global-reporting-initiative-gri-index.jpg?quality=85",
            "https://img.yumpu.com/407963/1/184x260/gsk-human-rights-statement.jpg?quality=85",
            "https://img.yumpu.com/407849/1/184x260/glaxosmithkline-plc-ehs-report-2003.jpg?quality=85",
            "https://img.yumpu.com/407846/1/184x260/form-20-f-glaxosmithkline-plc.jpg?quality=85",
            "https://img.yumpu.com/407843/1/184x260/q42010-full-year-results-announcement.jpg?quality=85",
            "https://assets.yumpu.com/release/Gb2iuBFx8UHm6GO/v5/img/logo/yumpu-footer2x.png",
            "https://assets.yumpu.com/v5/img/footer/worldmap-retina.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "gsk",
            "company",
            "shares",
            "financial",
            "executive",
            "directors",
            "share",
            "annual",
            "million",
            "business",
            "value",
            "www.gsk.com"
        ],
        "tags": null,
        "authors": [
            "Yumpu.com"
        ],
        "publish_date": null,
        "summary": "",
        "meta_description": "GSK Form 20F 2007",
        "meta_lang": "en",
        "meta_favicon": "https://assets.yumpu.com/release/Gb2iuBFx8UHm6GO/v5/img/logo/icon-favicon.png",
        "meta_site_name": "yumpu.com",
        "canonical_link": "https://www.yumpu.com/en/document/view/408081/gsk-form-20f-2007",
        "text": "As filed with the Securities and Exchange Commission on February 29, 2008 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, <strong>2007</strong> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 1-15170 GlaxoSmithKline plc (Exact name of Registrant as specified in its charter) England (Jurisdiction of incorporation or organization) 980 Great West Road, Brentford, Middlesex TW8 9GS England (Address of principal executive offices) Simon Bicknell Company Secretary GlaxoSmithKline plc 980 Great West Road Brentford England 011 44 20 8047 5000 company.secretary@gsk.com (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange On Which Registered American Depositary Shares, each representing 2 New York Stock Exchange Ordinary Shares, Par value 25 pence Securities registered or to be registered pursuant to Section 12(g) of the Act: None (Title of class) Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None (Title of class) Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes No Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections. Indicate by check mark whether the registrant (1) has filed all reports to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Securities Exchange Act of 1934. (Check one): Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: Ordinary Shares of 25p each 5,508,392,868 Large accelerated filer Accelerated filer Non-accelerated filer U.S. GAAP International Financial Reporting Standards as issued by the International Accounting Standards Board Other If “Other” has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow. Item 17 Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). OR OR OR Yes No"
    }
}